Adaptimmune Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch ADAPY and buy or sell other stocks, ETFs, and their options commission-free!About ADAPY
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8.
CEOChristopher James Hill
CEOChristopher James Hill
Employees506
Employees506
HeadquartersAbingdon, Oxfordshire
HeadquartersAbingdon, Oxfordshire
Founded2014
Founded2014
Employees506
Employees506
ADAPY Key Statistics
Market cap12.48M
Market cap12.48M
Price-Earnings ratio-0.07
Price-Earnings ratio-0.07
Dividend yield—
Dividend yield—
Average volume4.77M
Average volume4.77M
High today$0.0563
High today$0.0563
Low today$0.0411
Low today$0.0411
Open price$0.0485
Open price$0.0485
Volume1.28M
Volume1.28M
52 Week high$0.74
52 Week high$0.74
52 Week low$0.0202
52 Week low$0.0202
Stock Snapshot
With a market cap of 12.48M, Adaptimmune Therapeutics(ADAPY) trades at $0.05. The stock has a price-to-earnings ratio of -0.07.
During the trading session on 2025-11-25, Adaptimmune Therapeutics(ADAPY) shares reached a daily high of $0.06 and a low of $0.04. At a current price of $0.05, the stock is +14.6% higher than the low and still -16.3% under the high.
Trading activity shows a volume of 1.28M, compared to an average daily volume of 4.77M.
Over the past 52 weeks, Adaptimmune Therapeutics(ADAPY) stock has traded between a high of $0.74 and a low of $0.02.
Over the past 52 weeks, Adaptimmune Therapeutics(ADAPY) stock has traded between a high of $0.74 and a low of $0.02.